CSIMarket Company Name, Ticker, Suppliers, else..
 
Nucana Plc  (NASDAQ: NCNA)
Other Ticker:  
 
 
Price: $0.7896 $-0.02 -2.156%
Day's High: $0.814 Week Perf: -4.87 %
Day's Low: $ 0.77 30 Day Perf: -25.51 %
Volume (M): 19 52 Wk High: $ 9.46
Volume (M$): $ 15 52 Wk Avg: $2.68
Open: $0.80 52 Wk Low: $0.18



 Market Capitalization (Millions $) 41
 Shares Outstanding (Millions) 52
 Employees 18
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -28
 Cash Flow (TTM) (Millions $) 42
 Capital Exp. (TTM) (Millions $) 0

Nucana Plc
Nucana Plc is a clinical-stage biopharmaceutical company that develops and commercializes innovative oncology treatments. The company focuses on developing proprietary medicines based on its ProTide technology, which enables the potent transformation of nucleoside analogs into novel prodrugs. These prodrugs aim to improve the therapeutic index of cancer treatments by increasing their efficacy and reducing toxicities. Nucana's lead product candidate, Acelarin, is currently being evaluated in clinical trials for multiple cancer indications, including colorectal and ovarian cancers. The company is committed to advancing the field of oncology and improving patient outcomes through the development of novel and targeted therapies.


   Company Address: NuCana plc Edinburgh 0
   Company Phone Number: 357 1111   Stock Exchange / Ticker: NASDAQ NCNA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
FBIO   -2.29%    
HCM   -0.99%    
MEIP   -0.65%    
XNCR        1.69% 
ZLAB   -8.5%    
ZYME        1.11% 
• View Complete Report
   



Product Service News

The Ascendant Potency of Innovation NuCana plc Secures Patent for NUC-7738 Amidst Challenging Financial Winds

Published Wed, Sep 25 2024 8:01 PM UTC

In the venerated halls of scientific inquiry and pharmaceutical advancement, there emerges a beacon of promise as NuCana plc, that eminent biopharmaceutical entity headquartered in the fair city of Edinburgh, recently proclaimed the auspicious grant of a composition-of-matter patent from the distinguished United States Patent and Trademark Office (USPTO). This noteworthy pat...
Clinical Study

Balancing Hope and Financial Reality The Case of NUC-7738 in Melanoma Treatment

Published Sat, Sep 14 2024 7:01 AM UTC

AbstractAs the fight against melanoma continues, innovative therapeutic combinations are critical for managing patients who are refractory or resistant to existing treatments. Nucana Plc s recent presentation at the ESMO Congress 2024 highlights promising results for NUC-7738 in combination with pembrolizumab. However, the company faces financial challenges that cast a shad...
Clinical Study

NuCanas Turning Point Discontinuation of NuTide323 Amidst Strategic Reassessments in Colorectal Cancer Treatments

Published Thu, Aug 29 2024 8:01 PM UTC

NuCana Plc has recently taken a critical step in its clinical development strategy by announcing the discontinuation of its Phase 2 randomized colorectal cancer study, referred to as NuTide:323. This decision follows a pre-planned initial analysis and recommendation from the study s steering committee, highlighting a potential pivot in the company?s focus and resources. Key...
Shares

NuCana PLC Meets Nasdaq's Minimum Bid Price Requirement and Implements ADS Ratio Change, Reinforcing its Market Position

Published Wed, May 1 2024 8:01 PM UTC

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement
NuCana plc, a pharmaceutical company based in Edinburgh, United Kingdom, has announced that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Stock Market, LLC (Nasdaq). The company received a notification letter from the Listing Qualifications Departme...
Shares

NuCana plc Implements ADS Ratio Change, Offering Greater Liquidity and Potential Upsides for Shareholders Amidst Stock Performance Challenges

Published Tue, Apr 16 2024 12:01 PM UTC

NuCana plc, a pharmaceutical company based in Edinburgh, United Kingdom, recently announced a significant change that will have a profound impact on its shareholders. The company has successfully altered the ratio of its American Depositary Shares (ADSs) to ordinary shares, moving from the existing one ADS representing one ordinary share to one ADS representing twenty-five o...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com